Dupixent®(dupilumab) late-breaking dataat AAD show significant improvements in signs and symptomsofmoderate-to-severe atopic hand and foot dermatitis
- More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks
- Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week
Paris and Tarrytown, N.Y. March18, 2023. Positive results from the clinical trial assessing Dupixent® (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented today. The trial, the first evaluating a biologic for this difficult-to-treat population, met its primary and key secondary endpoints. The results were featured in a late-breaking session, one of more than 20 Dupixent scientific presentations, at the American Academy of…